Smruthi Organics Limited manufactures and markets active pharmaceutical ingredient (API) products to India. The company provides API for cardiovascular that includes amlodipine besilate, losartan potassium, telmisartan, s - amlodipine besilate, s - amlodipine malelate, and valsartan; for anti diabetic, which comprises metformin HCL, vildagliptin, teneligliptin, and dapagliflozin; and for anti infectives that consists of ciprofloxacin HCL, diloxanide furoate, norfloxacin, and pefloxacin mesylate, as well as ticagrelor for anti platelets. It also offers drug intermediates, such as amlodipine base, s-amlodipine base, and phthaloyl amlodipine. In addition, the company is developing empagliflozin for anti-diabetics; and apixaban and rivaroxaban for anti-platelets. It also exports its products. The company was incorporated in 1989 and is headquartered in Solapur, India.
| Current Price | ₹121.70 |
|---|---|
| Market Cap | ₹139 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 40.7 |
| Return on Equity | 4.72% |
| 52-Week Range | ₹95.00 – ₹164.00 |
| Beta (1Y) | 0.76 |
| Dividend Yield | 1.23% |
1. API-99.7% 2. Formulation-0.2% 3. Unallocable-0%
Smruthi Organics Ltd is trading at ₹121.70, with a market capitalisation of ₹139 Cr.
Smruthi Organics Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Smruthi Organics Ltd has a P/E of 40.7 and a return on equity of 4.72%.